P.O. Box 134
Malvern, PA 19355
United States
610 725 1500
https://www.galeratx.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 7
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. J. Mel Sorensen M.D. | CEO, President & Director | 632.64k | N/A | 1957 |
Dr. Robert A. Beardsley M.B.A., Ph.D. | Co-Founder & COO | 464.59k | N/A | 1962 |
Mr. Christopher Degnan | Chief Financial Officer | 474.05k | N/A | 1980 |
Ms. Jennifer Evans Stacey Esq. | Chief Legal & Compliance Officer and Secretary | N/A | N/A | 1965 |
Ms. Andie Collier | Chief Regulatory & Quality Affairs Officer | N/A | N/A | N/A |
Ms. Judy Schnyder | Senior Vice President of Clinical Operations & Data Management | N/A | N/A | N/A |
Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
Galera Therapeutics, Inc.’s ISS governance QualityScore as of 29 April 2024 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder rights: 7; Compensation: 7.